The 4 bullish analyst ratings for Cullinan Oncology indicate a positive outlook for the stock. With an average price target of $49.5, which is significantly higher than its current price of $9.56, it suggests that the stock has potential for growth in the short term. The decrease in the average price target from $50.00 to $49.5 is minimal and does not significantly impact the overall bullish sentiment.